^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

EPZ031686

i
Other names: EPZ031686, EPZ 031686, EPZ-031686
Associations
Trials
Company:
Ipsen
Drug class:
SMYD3 inhibitor
Associations
Trials
over3years
Discovery of the 4-aminopiperidine-based compound EM127 for the site-specific covalent inhibition of SMYD3. (PubMed, Eur J Med Chem)
In enzymatic assays, 11C showed a stronger SMYD3 inhibitory effect compared to the reference inhibitor EPZ031686...Furthermore, 11C (5 μM) strongly decreased the steady-state mRNA levels of genes important for tumor biology such as cyclin dependent kinase 2, c-MET, N-cadherin and fibronectin 1, all known to be regulated, at least in part, by SMYD3. Thus, 11C is as a first example of second generation SMYD3 inhibitors; this agent represents a covalent and a site specific SMYD3 binder capable of potent and prolonged attenuation of methyltransferase activity.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase) • FN1 (Fibronectin 1) • CDK2 (Cyclin-dependent kinase 2) • CDH2 (Cadherin 2) • SMYD3 (SET And MYND Domain Containing 3) • NECTIN1 (Nectin Cell Adhesion Molecule 1)
|
EPZ031686